drugset / Trial / NCT00459069
The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma
Phase 1
Completed
18 enrolled
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital · collabDana-Farber Cancer Institute · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to test the safety of dendritic cell tumor fusion study vaccine and to determine the type and severity of any side effects associated with this study vaccine. Cancer cells have unique markers that distinguish them from normal cells of the body. These markers can potentially serve as targets for the immune system. Dendritic cells are normally found in small amounts in the body and are responsible for immune responses against "foreign" substances that enter the body. Animal studies have shown that these fused cells can stimulate powerful anti-tumor responses.
Timeline
- Start
- 2004-07
- Primary completion
- 2008-06
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dendritic Cell Tumor Fusion Vaccine | Vaccine | — | Subcutaneous |